FDA Approves New Immunotherapy for Blood Cancers

The U.S. FDA has granted approval for Tregzi, an allogeneic regulatory T cell-based immunotherapy. This treatment is intended for adults with hematologic malignancies undergoing stem cell transplantation. Its purpose is to aid in immune system reconstitution and enhance survival free from chronic graft-versus-host disease.